📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors. (2019)

First Author: Blunt MD

Attributed to: Using MHC class I peptides to modulate NK cell activity, as a basis for immunotherapy funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/tan.13413

PubMed Identifier: 30381896

Publication URI: http://europepmc.org/abstract/MED/30381896

Type: Journal Article/Review

Volume: 93

Parent Publication: HLA

Issue: 1

ISSN: 2059-2302